Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline vs Moxifloxacin for CABP in Chinese Adults
NCT06162286Phase 3Recruiting
- Sponsor
- Zai Lab
- Start
- Nov 2023
- Primary completion
- Jan 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of omadacycline in community-acquired bacterial pneumonia (CAP), sponsored by Zai Lab. Started Nov 2023; status: recruiting.
02
Drugs
omadacycline
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT06162286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162286.